Abbisko Therapeutics Co., Ltd (HKG: 2256) and Allist Pharmaceuticals Co., Ltd have announced the upcoming start of a multi-center, open Phase II clinical study to evaluate the combination of Abbisko’s ABSK043 and Allist’s furmonertinib in patients with advanced non-small cell lung cancer (NSCLC). The study aims to establish the optimal dosage for the ABSK043/furmonertinib combination, which will inform further exploratory studies.
Abbisko’s ABSK043 is an orally administered, in-house developed programmed-death ligand 1 (PD-L1) inhibitor currently undergoing Phase I clinical studies for advanced solid tumors in Australia and China.
Allist’s furmonertinib, an in-house discovery, is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor co-developed with ArriVent outside of Greater China under a deal signed in 2021. Initially approved in China in March 2021 for patients with locally advanced or metastatic NSCLC harboring an EGFR T790M mutation, the drug later expanded its indication in June 2022 to include first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations. Furmonertinib is currently in Phase III studies for NSCLC with sensitive EGFR mutations as adjuvant therapy and first-line NSCLC with rare EGFR mutations. The drug has previously received breakthrough therapy designation (BTD) in the US and China for the treatment of NSCLC with EGFR 20 exon insertion mutations.- Flcube.com
